Description
The presence of a mutation in the PDGFRa gene is a predictor of response to imatinib therapy in patients with gastrointestinal stromal tumors (in cases of unresectable tumors, recurrence, or metastatic disease).
Period of execution
Within 12 days. The specified time does not include the day of biomaterial collection
Biomaterial type
- Tissue sample
- Tissue sample in paraffin block